EVOK - Evoke stock down 24% as study shows lower risk of tardive dyskinesia among patients treated with metoclopramide

Evoke Pharma (NASDAQ:EVOK) announced on Monday that a real-world data analyses showed a lower risk of tardive dyskinesia among gastroparesis patients treated with metoclopramide compared to previous reports. Evoke's flagship product, Gimoti, is an FDA-approved nasal formulation of metoclopramide and is specifically designed to deliver a non-oral dose of the drug to treat adults with acute and recurrent diabetic gastroparesis. The study concluded that tardive dyskinesia (TD) was rare among metoclopramide-treated patients, with an incidence of 33.4 per 100,000, and among metoclopramide-treated gastroparesis patients, it was 98.8 per 100,000. Tardive Dyskinesia is characterized by uncontrolled movements of the face and body. The highest TD incidence were reported among elderly females, the study showed. The incidence of TD was also found to increase with prolonged metoclopramide use, with the greatest risk of TD observed after 24 to 48 months of chronic metoclopramide use. The stock fell 24.5% before the bell. The data were presented at DDW,

For further details see:

Evoke stock down 24% as study shows lower risk of tardive dyskinesia among patients treated with metoclopramide